HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil
10 déc. 2020 07h45 HE
|
HalioDx
HalioDx Partners with DASA, the Largest Diagnostics Provider in Latin America, to make Immunoscore® available in Brazil Marseille, France, December 10, 2020 HalioDx SAS, the immuno-oncology...
Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients
03 déc. 2020 07h45 HE
|
HalioDx
Expanding Immunoscore® clinical utility on 3000+ stage III colon cancer patients Marseille, France, December 03, 2020 HalioDx SAS, the immuno-oncology diagnostic company pioneering the immunological...
New data reinforces Immunoscore clinical utility in localized Colon Cancer
20 oct. 2020 08h00 HE
|
HalioDx
New data reinforces Immunoscore clinical utility in localized Colon Cancer Changes in patterns of oncology care with the incorporation of immune response in a study of Stage II colon cancer...
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center
09 oct. 2020 08h00 HE
|
HalioDx
Paltown Development Foundation and HalioDx Team Up for Colorectal Cancer Testing Center COLONTOWN University Launches Secure Platform for Colorectal Cancer Patients Marseille, France, October 9,...
HalioDx contribution to precision medicine at ESMO 2020
18 sept. 2020 08h10 HE
|
HalioDx
HalioDx contribution to precision medicine at ESMO 2020 Marseille, France, September 18, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that, at the European Society of...
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer
10 sept. 2020 07h45 HE
|
HalioDx
Immunoscore® to select patients in the POCHI trial, a phase II multicenter trial testing immunotherapy with chemotherapy and bevacizumab in metastatic colorectal cancer Marseille, France, September...
Immunoscore included in ESMO Clinical Practice Guidelines 2020
06 août 2020 07h45 HE
|
HalioDx
Immunoscore® included in ESMO Clinical Practice Guidelines 2020 Marseille, France, August 06, 2020 HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been...
New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer
26 mai 2020 07h45 HE
|
HalioDx
New evidence from 2 pivotal studies reinforces clinical value of Immunoscore® In Colon Cancer Two large Immunoscore® studies from Phase III trials published in JNCI Cancer Spectrum & Annals of...
HalioDx's expertise applied to ImCheck’s EVICTION Trial
19 mai 2020 07h50 HE
|
HalioDx
HalioDx to Characterize the Immune Contexture ofPatients Enrolled in ImCheck’s EVICTION Phase 1/2 Clinical Trial HalioDx’s immunoscoring technologies to characterize patients treated with ImCheck’s...